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Objective: To use structure-activity analysis to study the anti-Alzheimer's disease (anti-
AD) activity of natural coumarins isolated from Angelica decursiva and Artemisia
capillaris, along with one purchased coumarin (daphnetin).
Methods: Umbelliferone, umbelliferone 6-carboxylic acid, scopoletin, isoscopoletin, 7-
methoxy coumarin, scoparone, scopolin, and esculetin have been previously isolated;
however 20-isopropyl psoralene was isolated from Angelica decursiva for the ﬁrst time to
evaluate their inhibitory effects against acetylcholinesterase (AChE), butyr-
ylcholinesterase (BChE), and b-site amyloid precursor protein cleaving enzyme 1
(BACE1) enzyme activity. We scrutinized the potentials of coumarins as cholinesterase
and BACE1 inhibitors via enzyme kinetics and molecular docking simulation.
Results: Among the test compounds, umbelliferone 6-carboxylic acid, esculetin and
daphnetin exhibited potent inhibitory activity against AChE, BChE and BACE1. Both
esculetin and daphnetin have a catechol group and exhibit signiﬁcant anti-AD activity
against AChE and BChE. In contrast, presence of a sugar moiety and methoxylation
markedly reduced the anti-AD activity of the coumarins investigated in this study. With
respect to BACE1 inhibition, umbelliferone 6-carboxylic acid, esculetin and daphnetin
contained carboxyl or catechol groups, which signiﬁcantly contributed to their anti-AD
activities. To further investigate these results, we generated a 3D structure of BACE1
using Autodock 4.2 and simulated binding of umbelliferone 6-carboxylic acid, esculetin
and daphnetin. Docking simulations showed that different residues of BACE1 interacted
with hydroxyl and carboxylic groups, and the binding energies of umbelliferone 6-
carboxylic acid, esculetin and daphnetin were negative (−4.58, −6.25 and −6.37 kcal/
mol respectively).
Conclusions: Taken together, our results suggest that umbelliferone 6-carboxylic acid,
esculetin and daphnetin have anti-AD effects by inhibiting AChE, BChE and BACE1,
which might be useful against AD.7, Republic of Korea.
lic of Korea.
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Alzheimer's disease (AD) is the major form of dementia and
is a deadly neurodegenerative disease that is progressive in na-
ture and develops through a multifactorial process. AD is the
fourth leading cause of death in developed countries, and pre-
dominates in Europe and USA following cardiovascular disease,
cancer, and stroke [1]. The two most common hypotheses used to
describe the pathology of AD are known as the ‘cholinergic
hypothesis’ and ‘amyloid hypothesis’. The cholinergic
hypothesis suggests that AD is caused by a deﬁciency in the
brain levels of the cerebral neurotransmitter acetylcholine
(ACh), which is hydrolyzed by acetylcholinesterase (AChE)
[2]. Similarly, butyrylcholinesterase (BChE) activity is
increased by 40%–90% during the progression of AD [3], and
BChE inhibition is considered a potentially important aspect
of treating AD. In addition to the AChE and BChE
hypotheses, accumulation of amyloid-b peptide (Ab) in the
brain is widely considered to be critically involved in the
pathogenesis of AD [4]. Ab plaques emerge roughly 15 years
before the symptoms of AD appear [5], and once AD develops
the cognitive decline caused by neuronal damage cannot be
reversed, even after Ab levels in the brain are lowered by
immunotherapy [6]. Thus, prevention of Ab accumulation is
considered an important part of preventing AD. Ab is excised
from amyloid-b precursor protein through sequential cleavage
by aspartic protease b-secretase 1 (BACE1) [4]. Thus, because
BACE1 initiates Ab processing, inhibition of BACE1 activity
may be an effective way to prevent Ab accumulation [7].
Coumarins are an important class of natural compounds and
are used as additives in both foods and cosmetics [8]. Coumarin
has been reported to have antibacterial [9], anti-oxidant [10], anti-
inﬂammatory and anticoagulant [11], and anti-AD activities [12].
Coumarins are characterized a fused benzene and a-pyrone ring
that serves as the structural nucleus. Importantly, a number of
studies have demonstrated the ability of coumarins to inhibit
AChE [12–14], and the benzopyrone structural nucleus of
coumarins is an essential aspect of hybrid molecules capable
of simultaneously inhibiting AChE and AChE-induced b-amy-
loid aggregation [15]. Likewise, the possibility of numerous
chemical substitutions afforded by the structural nucleus
makes coumarins interesting molecules for drug discovery.
As part of our continuing efforts to identify compounds from
natural resources that inhibit AChE, BChE, and BACE1, we
recently found that the methanolic extract of Angelica decursiva
(A. decursiva) (Umbelliferae) fulﬁlls these criteria [16]. This
plant is used traditionally as an anti-inﬂammatory, diuretic, ex-
pectorant, and diaphoretic, as well as a remedy for colds,
inﬂuenza, hepatitis, arthritis, indigestion, coughs, chronic bron-
chitis, pleurisy, typhoid, headaches, ﬂatulence, fever, colic,
travel sickness, rheumatism, bacterial and fungal infections, and
diseases of the urinary organs [17,18]. Furthermore, extensive
investigations of different species of this genus have been
carried out in the last decade, and as a result many classes of
compounds have been isolated including different types of
coumarin derivatives [19]. In addition, Artemisia capillaris
(A. capillaris) is commonly distributed in sandy areas along
the Korean coastline. This plant has been frequently used in
the treatment of liver disease, including hepatitis, jaundice,
fatty liver and bilious disorder. Infusions of the buds, stems
and whole plant of A. capillaris have been used in traditional
Chinese medicine primarily as a choleric, anti-inﬂammatory,antipyretic, and diuretic agent for treating epidemic hepatitis
[20,21]. This study deals with the anti-AD activities and the
structure–activity relationship of coumarins isolated from
A. decursiva and A. capillaris. Speciﬁcally, because there is
currently no detailed information regarding the molecular in-
teractions between umbelliferone 6-carboxylic acid, esculetin,
daphnetin and BACE1, we performed molecular docking anal-
ysis and detailed enzyme kinetic analysis in order to investigate
the possibility of using compounds umbelliferone 6-carboxylic
acid, esculetin and daphnetin as potent anti-AD drug candidates.
2. Materials and methods
2.1. General experimental procedures
The 1H- and 13C-NMR spectra were determined using a
JEOL JNM ECP-400 spectrometer (Tokyo, Japan) at 400 MHz
for 1H and 100 MHz for 13C in deuterated chloroform (CDCl3).
Column chromatography was conducted using silica gel 60 (70–
230 mesh, Merck, Darmstadt, Germany). All TLC analyses were
conducted using pre-coated Merck Kieselgel 60 F254 plates
(20 cm × 20 cm, 0.25 mm) and using 50% H2SO4 as the spray
reagent.
2.2. Chemicals and reagents
Electric-eel acetylcholinesterase (AChE, EC3.1.1.7), horse-
serum butyrylcholinesterase (BChE, EC 3.1.1.8), acetyl thio-
choline iodide (ACh), butyrylthiocholine chloride (BCh), 5,50-
dithiobis [2-nitrobenzoic acid] (DTNB), quercetin, daphnetin
and berberine were purchased from E. Merck, Fluka, or Sigma–
Aldrich unless otherwise stated. The BACE1 FRET assay kit (b-
secretase) was purchased from Pan Vera Co. (Madison, WI,
USA). All chemicals and solvents used for column chromatog-
raphy were of reagent grade, purchased from commercial sour-
ces, and used as received.
2.3. Isolation of coumarins
Umbelliferone, umbelliferone 6-carboxylic acid, scopoletin,
isoscopoletin, 7-methoxy coumarin, scoparone, scopolin and
esculetin were isolated from A. decursiva and A. capillaris, ac-
cording to the method described by Zhao et al. [18] and Islam
et al. [21], respectively. 20-Isopropyl psoralene was isolated
from subfraction-2 of dichloromethane fraction from A. decur-
siva, and identiﬁed by spectroscopic evidence including 1H and
13C–NMR, as well as by comparison with spectral published
data [22].
2.4. In vitro ChE enzyme assay
The inhibitory activities of the isolated coumarins towards
ChE were measured using the spectrophotometric method
developed by Ellman et al. [23]. ACh and BCh were used as
substrates to assay the inhibition of AChE and BChE,
respectively. Each reaction mixture consisted of 140 mL
sodium phosphate buffer (pH 8.0), 20 mL of test sample
solution at a ﬁnal concentration of 100 mM for all compounds,
and 20 mL of either AChE or BChE solution, which were then
combined and incubated for 15 min at room temperature. All
test samples and positive control (berberine) were dissolved in
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DTNB and 10 mL of either ACh or BCh, respectively. The
enzymatic hydrolysis mediated by AChE or BChE was
monitored according to the formation of the yellow 5-thio-2-
nitrobenzoate anion at 412 nm for 15 min, which was due to the
reaction of DTNB with thiocholine released from ACh or BCh,
respectively. All reactions were performed in 96-well plates in
triplicate and recorded using a microplate spectrophotometer
(Molecular Devices).
2.5. In vitro BACE1 enzyme assay
The in vitro BACE1 enzyme assay was carried out according
to the manufacturers recommended protocol with minor modi-
ﬁcations. Brieﬂy, a mixture of 10 mL of assay buffer (50 mM
sodium acetate, pH 4.5), 10 mL of BACE1 (1.0 U/mL), 10 mL of
the substrate (750 nM Rh-EVNLDAEFK-Quencher in 50 mM,
ammonium bicarbonate) and 10 mL of the test samples were
dissolved in 10% DMSO and incubated for 60 min at 25 C in
the dark. The proteolysis of two ﬂuorophores (Rh-EVNL-
DAEFK-Quencher) by BACE1 was determined by monitoring
formation of the ﬂuorescent donor (Rh-EVNL) at wave lengths
of 530–545 nm for excitation and 570–590 nm for emission.
Fluorescence was measured with a microplate spectroﬂuorom-
eter (Gemini EM, Molecular Devices, and Sunnyvale, CA,
USA). Speciﬁcally, each reaction was excited at 545 nm and the
emission intensity was recorded at 585 nm.
2.6. Kinetic parameters of different coumarins towards
AChE, BChE and BACE1 inhibition
In order to determine the mechanism of inhibition of the
different coumarins, AChE and BChE inhibition was evaluated
by monitoring the effects of different concentrations of substrate
(0.6–0.1 mM for different samples). Speciﬁcally, AChE and
BChE inhibition assays were performed as described above, but
the substrate concentration was varied. Reactions were initiated
upon addition of 10 mL of DTNB and 10 mL of either Ach or
Bch at the indicated concentrations. In addition, to determine the
kinetic mechanisms of the different coumarins towards BACE1,
we employed two complementary kinetic methods, namely
Lineweaver–Burk and Dixon plots [24,25]. Speciﬁcally, Dixon
plots for inhibition of BACE1 by umbelliferone 6-carboxylic
acid, esculetin and daphnetin were obtained in the presence of
different concentrations of substrate: 375 nM (;); 250 nM (B)
and 150 nM (C). Likewise, the test concentrations of umbel-
liferone 6-carboxylic acid, esculetin and daphnetin for the
BACE1 inhibition kinetic analysis were 0.1 mM (;), 1 mM (B),
and 10 mM (C) for umbelliferone 6-carboxylic acid; 2.5 mM
(;), 12.5 mM (B), and 62.5 mM (C) for esculetin; and 2.5 mM
(;), 25 mM (B), and 100 mM (C) for daphnetin. Inhibition
constants (Ki) were determined by interpretation of Dixon plots,
where the value of the x-axis intercept was taken as Ki [25,26].
2.7. BACE1 molecular docking simulations
To estimate the structure of the enzyme–inhibitor complex
and to ensure accuracy, repeatability, and reliability of docking
results, we employed Autodock 4.2 software. In our study, the
test concentrations of coumarins for AChE were 100 mM,
50 mM, and 10 mM for umbelliferone 6-carboxylic acid,100 mM, 20 mM, and 4 mM for esculetin; and 100 mM, 50 mM,
and 25 mM for daphnetin. Likewise, the test concentrations for
BChE were 100 mM, 50 mM and 25 mM for umbelliferone 6-
carboxylic acid; 100 mM, 20 mM, and 1 mM for esculetin; and
50 mM, 25 mM, and 10 mM for daphnetin. Speciﬁcally, we used
Autodock 4.2 to dock different coumarins into the binding site
of the BACE1 crystallographic structure, which was deﬁned as
all residues 5–6 Å from the inhibitor in the original complex.
Autodock 4.2 uses a semi-empirical free energy force ﬁeld to
predict binding free energies of protein–ligand complexes of
known structures and binding energy for both bound and un-
bound states. Twelve ligand structures were constructed and
minimized using Chemdraw and LigandScout software for 2D
and 3D conformations, respectively. For docking studies, the
crystal structure of the BACE1 protein target was obtained from
the protein sequence alignment [Protein Data Bank (PDB ID
2wjo)]. The 3D structures of umbelliferone 6-carboxylic acid,
esculetin and daphnetin were generated and minimized using
Chemdraw and LigandScout, for 2D and 3D conformation,
respectively.
2.8. Statistical analysis
All results are expressed as the mean ± SEM of triplicate
samples. Results were analyzed using one-way ANOVA and
Student's t-test where appropriate (Systat Inc., Evanston, IL,
USA). Values of P < 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Inhibitory activity of coumarins against AChE,
BChE and BACE1
In order to evaluate the anti-AD activity of the isolated
coumarins, we ﬁrst evaluated their abilities to inhibit AChE,
BChE, and BACE1. A total of 10 coumarin derivatives were
screened for their in vitro AChE, BChE and BACE1 inhibitory
capacities (Table 1). Our results showed that esculetin and
daphnetin exhibited good AChE inhibitory activity with IC50
values of 6.13 and 11.57 mM, while umbelliferone 6-carboxylic
acid, umbelliferone, scopoletin, isoscopoletin, 20-isopropyl
psoralene, as well as 7-methoxy coumarin showed moderate
inhibitory activities with IC50 values of 104.12, 145.19, 150.28,
153.77, 173.89, and 186.47 mM, respectively. Next we investi-
gated the BChE inhibitory activities of the isolated coumarins
(Table 1). The coumarins daphnetin, esculetin, and umbellifer-
one 6-carboxylic acid exhibited promising BChE inhibitory ac-
tivity with IC50 values of 8.66, 9.29, and 27.19 mM, which
compared favorably to the positive control berberine (IC50 of
7.01 mM). On the other hand, umbelliferone, isoscopoletin, 7-
methoxy coumarin, scopoletin, and 20-isopropyl psoralene
possessed only moderate inhibitory activity towards BChE with
IC50 values of 105.28, 110.30, 119.39, 159.30, and 179.22 mM,
respectively. Finally, with respect to BACE1 inhibitory activity,
umbelliferone 6-carboxylic acid, esculetin and daphnetin
exhibited strong inhibitory activity with IC50 values of 0.34,
7.67, and 11.19 mM compared to the positive control quercetin
13.98 mM. On the other hand, isoscopoletin, umbelliferone, and
7-methoxy coumarin exhibited moderate inhibitory activities
with IC50 values of 146.43, 143.1, and 172.26 mM respectively.
Table 1
ChEs and BACE1 inhibitory activities of coumarins isolated from A. decursiva and A. capillaris (IC50 (mM)) (mean ± SEM).
Test compounds AChEb BChEc SId BACE1e
Umbelliferone 145.19 ± 0.18 105.28 ± 1.02 0.72 143.1 ± 1.89
Umbelliferone 6-carboxylic acid 104.12 ± 0.11 27.19 ± 1.20 0.26 0.34 ± 0.01
Esculetin 6.13 ± 0.83 9.29 ± 0.18 1.51 7.67 ± 0.91
Daphnetin 11.57 ± 0.49 8.66 ± 0.18 0.74 11.19 ± 0.93
Scopoletin 150.28 ± 0.27 159.30 ± 1.02 1.06 >100
Isoscopoletin 153.77 ± 1.93 110.30 ± 0.39 0.71 146.43 ± 1.08
7-Methoxy coumarin 186.47 ± 0.86 119.39 ± 0.99 0.64 172.26 ± 0.96
Scoparone 259.47 ± 0.97 273.39 ± 1.94 1.05 >100
Scopolin >200 >200 – >100
20-Isopropyl psoralene 173.89 ± 1.19 179.22 ± 0.91 1.03 >100
Berberinef 0.717 ± 0.01 7.01 ± 0.31 – –
Querceting – – – 13.98 ± 0.51
b,c,e Final concentration of test samples were 100 mM, dissolved in 10% DMSO; dSI: selectivity index (BChE/AChE). fBerberine and gquercetin were
used as positive controls for the ChE and BACE1 assays, respectively.
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3.2. Kinetic parameters of coumarins on AChE and
BChE inhibition
In order to determine the manner of AChE and BChE inhi-
bition by the different isolated coumarins, we performed kinetics
analyses using different concentrations of substrate (0.2 mM–
0.6 mM) and inhibitors, and evaluated the results using Dixon
plots, which are a graphical method for determining the type of
enzyme inhibition. Dixon plots are generated by plotting the
reciprocal enzyme velocity (1/V) against inhibitor concentrationFigure 1. Dixon plot of the inhibition of AChE and BChE by umbelliferone 6-c
and inhibitor concentrations.
(A) umbelliferone 6-carboxylic acid [0.6 mM (C); 0.4 mM (B); and 0.2 mM (;
AChE], (C) daphnetin [0.6 mM (C); 0.3 mM (B); and 0.1 mM (;) of ACh
0.1 mM (;) of BChE], (E) esculetin [0.6 mM (C); 0.3 mM (B); and 0.1 mM
(;) of BChE].(I), and can be used to determine the dissociation or Ki for the
enzyme–inhibitor complex, in which the value of the x-axis
intercept is the Ki [26]. As shown in Figure 1A–C and Table 2,
the manner of inhibition of umbelliferone 6-carboxylic acid and
esculetin was noncompetitive with Ki values of 80.99 mM and
25.09 mM, while compound daphnetin exhibited mixed type
inhibition with a Ki value of 19.98 mM for AChE. Similarly,
Figure 1D–F and Table 2, indicated that the type of inhibition of
umbelliferone 6-carboxylic acid was noncompetitive with a Ki
value of 49.78 mM, whereas esculetin and daphnetin exhibited
mixed type inhibition with Ki values of 16.11 mM and 7.18 mM,
respectively.arboxylic acid, esculetin and daphnetin in the presence of different substrate
) of AChE], (B) esculetin [0.6 mM (C); 0.4 mM (B); and 0.2 mM (;) of
E], (D) umbelliferone 6-carboxylic acid [0.6 mM (C); 0.3 mM (B); and
(;) of BChE], and (F) daphnetin [0.6 mM (C); 0.4 mM (B); and 0.2 mM
Table 2
Mode of inhibition and dissociation constants (Ki) of coumarins for AChE, BChE and BACE1 based on enzyme kinetic plot.
Test compounds AChE BChE BACE1
Inhibition typea Ki (mM)
b Inhibition typeb Ki (mM)
a Inhibition typec Ki (mM)
d
Umbelliferone 6-carboxylic acid Noncompetitive 80.99 Noncompetitive 49.78 Mixed 2.08
Esculetin Noncompetitive 25.09 Mixed e 16.11 Mixed 17.99
Daphnetin Mixed 19.98 Mixed 7.18 Mixed 16.18
Quercetine – – – – Competitive 10.45
Berberinef NA NA NA NA – –
a, b Determined by Dixon plots. c,d Determined by Dixon and Lineweaver–Burk plots. e,f Positive controls. NA, not tested.
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inhibition
To determine the mode of enzyme BACE1 inhibition by the
different coumarins we performed kinetics analysis using Line-
weaver–Burk plots and Dixon plots [24–26] employing different
concentrations of substrate (150 nM, 250 nM, and 375 nM)
and inhibitors. Ki values were determined by interpretation of
Dixon plots as described above. The test concentrations of the
different coumarins were as follows: 10 mM, 1 mM, and
0.1 mM for umbelliferone 6-carboxylic acid; 62.5 mM,
12.5 mM and 2.5 mM for esculetin; and 100 mM, 25 mM, and
2.5 mM for daphnetin. As shown in Figure 2A–F and Table 2,
the manner of BACE1 inhibition of umbelliferone 6-carboxylic
acid, esculetin and daphnetin was mixed, with Ki values of
2.08 mM, 17.99 mM, and 16.18 mM, respectively. A lower Ki
value is indicative of tighter enzyme binding and thus a more
effective inhibitor. Thus, these results suggested that umbelli-
ferone 6-carboxylic acid, esculetin and daphnetin might be good
BACE1 inhibitors.Figure 2. Dixon plots of BACE1 inhibition by coumarins. Umbelliferone 6-ca
(A), esculetin (B), and daphnetin (C) were tested in the presence of differen
Lineweaver–Burk plots for BACE1 inhibition by coumarins. BACE1 inhibiti
indicated: 0.1 mM (;), 1 mM (B), and 10 mM (C) for umbelliferone 6-carboxy
and 2.5 mM (;), 25 mM (B), and 100 mM (C) for daphnetin (F).3.4. Molecular docking study of the inhibitory activity of
the coumarins against BACE1
To follow up our results for the most active BACE1 inhibitory
compounds we next performed molecular docking simulations.
Speciﬁcally, we used Autodock 4.2 to predict and investigate the
interactions between umbelliferone 6-carboxylic acid, esculetin,
daphnetin and BACE1. Molecular docking models of these three
coumarins and 2-Amino-3-{(1r)-1-cyclohexyl-2-[(cyclo-
hexylcarbonyl) amino] ethyl}-6-phenoxyquinazolin-3-Ium
(QUD) are illustrated in Figures 3–5. QUD is the most potent
nonpeptic BACE1 inhibitor reported to date according to protein
data bank. Ligand–enzyme complexes with umbelliferone 6-
carboxylic acid, esculetin, daphnetin and QUD were stably
posed in the same pocket of BACE1 by Autodock 4.2. As
illustrated in Figures 3–5, the corresponding ligand interactions
of umbelliferone 6-carboxylic acid in the active site of BACE1
were facilitated by hydrogen-bonding interactions between the
Arg235 residue and one carboxylic group interaction between
each of the Tyr71, Arg235 and Thr72 residues with one hydroxylrboxylic acid.
t concentrations of substrate: 150 nM (C), 250 nM (B), 375 nM (;).
on was analyzed in the presence of different concentrations of sample as
lic acid (D); 2.5 mM (;), 12.5 mM (B), and 62.5 mM (C) for esculetin (E);
Figure 3. (A) Molecular docking model of BACE1 with umbelliferone 6-carboxylic acid (red color) and QUD (blue color). (B) Diagram of the ligand
interaction of umbelliferone 6-carboxylic acid in the active site of BACE1.
Figure 4. (A) Molecular docking model of BACE1 with esculetin (magenta color) and QUD (white color). (B) Diagram of the ligand interaction of esculetin
in the active site of BACE1.
Figure 5. (A) Molecular docking model of BACE1 with daphnetin (magenta color) and QUD (white color). (B) Diagram of the ligand interaction of
daphnetin in the active site of BACE1.
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corresponding ligand interaction for esculetin in the active site of
BACE1 consisted of two hydrogen-bonding interactions with the
Asn37, Ser36, and Ile126 residues of BACE1 and two hydroxyl
groups of the compound, while binding of daphnetin in the active
site of BACE1 was mediated by two hydrogen-bonding in-
teractions with Asp259 and Phe257 residues of the enzyme and
two hydroxyl groups of the compound. The binding energies of
these three compounds were −4.58, −6.25 and −6.37 kcal/mol,respectively, which compared favorably with that of QUD, which
had a binding energy of −10.99 kcal/mol. Taken together, these
results indicated that additional hydrogen bonding and carboxylic
groups might stabilize the open form of BACE1 and facilitate
tighter binding to the active site resulting in more effective
enzyme inhibition. Importantly, in vitro evaluation and in silico
molecular docking data both strongly suggest that umbelliferone
6-carboxylic acid, esculetin and daphnetin may inhibit and/or
prevent AD by targeting the formation of b-amyloid.
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Recognition of the ability of natural products to positively
impact health and well-being continues to grow both culturally
and scientiﬁcally. As a result, there is a growing interest in
demonstrating relationships between consumption of natural
products and risk reduction and/or prevention of various disease
and health conditions. As such, efforts to study and identify
added-value natural products with health-promoting properties
have also prompted the development of new drugs. For example,
the beneﬁts of natural products have been successfully demon-
strated in AD [27]. Although its etiology remains unknown, the
neuropathological proﬁle of AD is associated with memory
loss and is consistent with the presence of numerous plaques
and cholinergic deﬁciency due to the degeneration or atrophy
of cholinergic neurons in the basal forebrain [28]. With respect
to the regulation of cognitive functions, the central cholinergic
system is considered to be the most important neurotransmitter
[29]. Indeed, cholinesterases such as AChE and BChE are
considered key enzymes that play signiﬁcant roles in
cholinergic transmission by hydrolyzing the neurotransmitter
Ach [30]. Loss of basal forebrain cholinergic cells results in an
important reduction of ACh, which is believed to play a
deﬁning role in the cognitive impairment associated with AD,
senile dementia, ataxia, and myasthenia gravis [29]. Moreover,
at the molecular level, patients affected by AD exhibit
abnormal deposits of Ab and abnormal spiral ﬁlaments in
neurons, increased oxidative stress, and low levels of Ach [31].
The death of neurons during the progression of AD usually
affects the levels of brain neurotransmitters. In addition to ACh,
other neurotransmitters such as glutamate and serotonin are also
affected during the later stages of AD [32]. There is unfortunately
no cure for AD, and treatment strategies are primarily
symptomatic. Thus, current efforts to develop new therapeutics
are focused on the cholinergic hypothesis, which aim to target
AChE inhibition to improve cholinergic neurotransmission in
the brain [33]. Interestingly, recent studies have shown that
AChE has additional non-cholinergic function by binding to
Ab [34]. Several of the cholinesterase inhibitors currently in use,
namely donepezil, tacrine, rivastigmine, and galantamine, have
adverse side-effects such as gastrointestinal disturbances,
nausea, vomiting, and diarrhea and also have bioavailability
issues [35]. For these reasons, there is growing scientiﬁc interest
in identifying natural sources of AChE, BChE and BACE1
inhibitors with safer proﬁles.
To evaluate the potential of coumarins as anti-AD agents, we
investigated their ability to inhibit AChE, BChE and BACE1
using a modiﬁed version of the assay described by Ellman et al.
[23]. A total of 10 coumarin derivatives were screened for their
ability to inhibit AChE, BChE and BACE1 in vitro. The
results of the screening showed that esculetin and daphnetin
had good AChE and BChE inhibitory activities with IC50
values of 6.13 and 11.57 mM for AChE, respectively, as well
as good BChE inhibitory activities with IC50 values of 8.66
and 9.29 mM, respectively. With respect to BACE1 inhibition,
umbelliferone 6-carboxylic acid, esculetin and daphnetin had
strong inhibitory activity with IC50 values of 0.34, 7.67, and
11.19 mM, respectively.
In order to establish a structure–activity relationship between
the coumarins and the target enzyme inhibition, the inhibitory
effects of all coumarins against AChE, BChE and BACE1 were
investigated. Among the molecules investigated, both esculetinand daphnetin, which have free hydroxyl groups at the 6, 7, or 8
positions, exhibited the highest inhibitory potential against
AChE. A comparison of the inhibitory potential of different
coumarin derivatives indicated that the presence of an o-dihy-
droxyl (catechol) group markedly increased inhibitory activity.
Umbelliferone has a free hydroxyl group at the 7 position
whereas umbelliferone 6-carboxylic acid contains both a free
hydroxyl group at the 7 position and a carboxylic group at po-
sition 6. Interestingly, despite this difference in structure, the
latter compound retained inhibitory activity, although it was
reduced compared to esculetin and daphnetin. Substitution with
a methoxyl or glycosyl group diminished the inhibitory potential
as evidenced by the activity of scopoletin, isoscopoletin, sco-
polin, scoparone, and 7-methoxy coumarin. 20-Isopropyl psor-
alene contains two methyl groups, which appeared to reduce its
inhibitory activity towards AChE. Based on the above structure–
activity relationship, the AChE inhibitory activity appears to be
largely dependent on the presence of the hydroxyl groups at the
6, 7, or 8 positions, with methoxylation and glycosylation at
these positions greatly diminishing inhibitor potency.
Regarding BChE inhibitory activity, umbelliferone 6-
carboxylic acid, esculetin and daphnetin showed signiﬁcant
inhibitory activity. In particular, daphnetin, esculetin, and
umbelliferone-6-carboxylic acid were as good as the positive
control berberine. Indeed, both daphnetin and esculetin, which
have a free hydroxyl group at the 6, 7, or 8 positions, displayed
the highest inhibitory potential against BChE. On the other hand,
umbelliferone and umbelliferone 6-carboxylic acid, which both
have a free hydroxyl group at the 7 position, retained inhibitory
activity but it was reduced compared to esculetin and daphnetin.
Similar to the results described above, methoxylation at the 6, 7,
or 8 positions (scopoletin, scopolin, scoparone and 7-methoxy
coumarin) drastically abolished inhibitory activity, while
glycosylation at the 7 position (isoscopoletin) resulted in com-
plete inactivity at the concentrations tested. Based on these ob-
servations, it was clear that the presence of a free hydroxyl group
is very important for BChE inhibitory activity. Importantly,
these results were similar to those described in previous anti-AD
studies [12].
In order to elucidate the relationship between structure and
activity, we investigated the ability of the different coumarins to
inhibit BACE1. Umbelliferone 6-carboxylic acid, esculetin, and
daphnetin exhibited promising inhibitory activity against
BACE1 compared to the positive control quercetin. Umbelli-
ferone 6-carboxylic acid has a free carboxyl group at the C-6
position while esculetin and daphnetin have free hydroxyl
groups at the C-6, 7, or 8 positions. Umbelliferone, iso-
scopoletin, and 7-methoxy coumarin had moderate inhibitory
activity against BACE1. Thus, based on our results, presence of
a free carboxyl and free hydroxyl group at the 6, 7 or 8 positions
of coumarin appears to be important for BACE1 inhibitory
activity.
Various active compounds and extracts obtained from me-
dicinal plants have been assessed for their efﬁcacy against AD
[36]. However, synergistic interactions are possible from plant
extracts due to the simultaneous presence of dozens of
bioactive compounds. Indeed, use of a single molecule for
disease treatment and research is often preferred in order to
better understand the mechanism of action. Therefore, it is
very important to elucidate the active components in plant
extracts. In the present study, we screened several pure
coumarin derivatives for their ability to inhibit cholinesterase
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concerning the anticholinesterase capacity of coumarins.
Previously, Kang et al. [37] showed that the methanolic extract
of Angelica gigas (A. gigas) roots (Umbelliferae) has
signiﬁcant anti-AChE activity, which ultimately led to the
isolation of twelve coumarin derivatives. Orhan et al. [38] has
been reported that coumarins have anticholinesterase activity.
Relevant to the present study, another furanocoumarin
derivative called nodakenin was isolated from A. gigas of
Korean origin and examined for its effect on learning and
memory impairment induced by scopolamine [39]. Decursinol,
a coumarin-type compound from A. gigas roots, was also
shown to have good anti-AChE effects [12]. In another study that
employed a structure-based pharmacophore model, the two
coumarins scopoletin and scopolin were investigated for their
ability to inhibit AChE using a bioautography thin-layer chro-
matography assay [40], the results of which were consistent with
our ﬁndings. Speciﬁcally, both scopoletin and scopolin had
moderate but nevertheless remarkable, dose-dependent, and
long-lasting inhibitory effects against AChE. On the other hand,
the CH2Cl2 extract of Peucedanum ostruthium roots was shown
to have signiﬁcant inhibitory effects on AChE [41], and through
bioactivity-guided fractionation four coumarin derivatives
(ostruthin, imperatorin, ostruthol, and oxypeucedanin hydrate)
were identiﬁed as the active components.
In an attempt to clarify the manner of AChE inhibition by the
active coumarins identiﬁed in this study, we performed kinetics
analyses using different substrate concentrations (0.6, 0.4, and
0.2 mM for umbelliferone 6-carboxylic acid and esculetin; 0.6,
0.3 and 0.1 mM for daphnetin) and analyzed the data using
Dixon plots. As shown in Figure 1A–C, the manner of inhibition
of umbelliferone 6-carboxylic acid and esculetin was noncom-
petitive with Ki values of 80.99 and 25.09 mM, respectively,
while daphnetin showed mixed type inhibition with a Ki value of
19.98 mM. Likewise, to determine the type of BChE inhibition,
we performed kinetics analysis of umbelliferone 6-carboxylic
acid, esculetin and daphnetin by monitoring the effects of
different concentrations of substrate (0.6–0.1 mM) and analyzed
the data by Dixon plots. As shown in our study, umbelliferone 6-
carboxylic acid exhibited noncompetitive type inhibition with a
Ki value of 49.78 mM, whereas esculetin and daphnetin showed
mixed type inhibition with Ki values of 16.11 and 7.18 mM,
respectively. Lastly, to clarify the mode of enzyme BACE1 in-
hibition by the most potent coumarins, kinetics analysis was
performed and the results were evaluated using Lineweaver–
Burk plots and Dixon plots [24–26] at different substrate (150,
250, and 375 nM) and inhibitor concentrations. In analyzing
the data, lower Ki values are indicative of tighter binding of
inhibitors to the enzyme and thus a more effective inhibitor.
Thus, the Ki values indicated that umbelliferone 6-carboxylic
acid, esculetin and daphnetin may be excellent candidates as
BACE1 inhibitors.
Based on our enzyme kinetic results regarding type of inhi-
bition and Ki of umbelliferone 6-carboxylic acid, esculetin and
daphnetin towards BACE1, we next analyzed the molecular
structure of BACE1/inhibitor complexes using Autodock 4.2
[42,43]. Speciﬁcally, we used this software to simulate binding
between BACE1 and inhibitors and evaluate the binding site-
directed inhibition of BACE1. The docking results for umbel-
liferone 6-carboxylic acid, esculetin and daphnetin returned
negative binding energies of −4.58, −6.25 and −6.37 kcal/mol,
respectively, suggesting that all three coumarins are high afﬁnityenzyme-inhibitors that are able to tightly bind to the active site
of BACE1. Autodock 4.2 is used to simulate inhibitors into the
binding sites of enzymes that are located at a distance of 5–6 Å,
and in this way molecular docking studies a powerful method to
predict substructures that ﬁt into binding pockets of enzyme in
order to study inhibition and activation. The ligand–enzyme
complexes with these three compounds and QUD were stably
posed in the same pocket of BACE1 by Autodock 4.2. The
corresponding ligand interactions of umbelliferone 6-carboxylic
acid in the active site of BACE1 consisted of one hydrogen-
bond between Arg235 and one carboxylic group interaction
between the Tyr71, Arg235 and Thr72 residues of BACE1 with
one hydroxyl group at C-7 and one carboxylic group. The cor-
responding ligand interactions of esculetin in the active site of
BACE1 comprised two hydrogen-bonding interactions between
the enzyme at Asn37, Ser36, and Ile126 with two hydroxyl
groups of esculetin, while the binding of daphnetin in the active
site of BACE1 consisted of two hydrogen-bonding interactions
between enzyme at Asp259 and Phe257 and two hydroxyl
groups. Taken together, the in vitro results and molecular
docking data indicated that umbelliferone 6-carboxylic acid,
esculetin and daphnetin have a strong potential to inhibit and
prevent AD by targeting b-amyloid formation through BACE1.
In summary, our isolated coumarins have a signiﬁcant ability
to inhibit BACE1, BChE, and AChE. Based on structure–ac-
tivity relationships of these coumarins, we speculated that the
presence of a free hydroxyl group (catechol) at the C-6, 7, and 8
positions plays a predominant role in AChE and BChE inhibi-
tion, while the presence of a carboxyl and catechol group plays a
crucial role in BACE1 inhibition. Taken together with molecular
docking data, the results of the present study suggest that
umbelliferone 6-carboxylic acid, esculetin and daphnetin may be
good candidates for development as therapeutic agents for the
treatment and prevention of AD by targeting b-amyloid forma-
tion. Further in vivo and cellular based studies are needed to help
clarify the detailed mechanism of action of these compounds in
the brain membrane and other organs.
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